Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07348367 · ClinicalTrials.gov registry record · NA
A Comparison of Radical Prostatectomy and Precision Prostatectomy in Low- and Intermediate-risk Prostate Cancers.
A NA study of Prostatectomy, sponsored by Henry Ford Health System.
- Recruiting
- Registry status
- NA
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT07348367 is a NA study of Prostatectomy that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 160 participants, above the 91-participant average among 4 other Prostatectomy trials with a reported enrollment target (76% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07348367, a NA study of Prostatectomy, is actively recruiting participants, sponsored by Henry Ford Health System.
- RECRUITING
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
Prostate cancer (PCa) management for low- and intermediate-risk patients often involves radical prostatectomy (RP), which achieves oncologic control but is associated with significant functional impairments, such as erectile dysfunction (50-70%) and urinary incontinence (5-20%). To address these issues, precision prostatectomy (PP) has emerged as a novel surgical approach that preserves functional structures while removing \>90% of prostate tissue. PP is thought to provide superior functional outcomes with acceptable oncological control by preserving the capsule, seminal vesicle (SV), and the surrounding neuronal nitric oxide synthase (nNOS) producing nerves on the side opposite to the dominant nodule while maximizing prostatic tissue removal. Early reports of PP demonstrate promising functional outcomes, with 90% of patients retaining sexual potency (Sexual Health Inventory for Men \[SHIM\] score ≥17) and 100% achieving continence (0-1 pads/day) by 12 months postoperatively. Importantly, PP only requires a different surgical technique, no more equipment, time, or labor is required. This means that there is no additional charge to patients, and it is covered the same by health insurance. While there are early results suggesting the superiority of PP, no randomized trials have yet to be performed. This study has two main aims: to demonstrate superiority of PP in terms of functional recovery while also establishing non-inferiority in oncologic outcomes compared to RP. This dual objective reflects the potential of PP to improve quality of life without compromising cancer control. Eligible patients will be randomized to either RP, which is the current standard of care, or PP using random blocked randomization using the Zelen design. The outcomes of interest will be measured at 12 months post-surgery. Functional outcomes will be measured using SHIM scores at 12 months and the number of pads used per day. Meanwhile, oncological outcomes will be measured by whether pat
Conditions Studied
Interventions
- PROCEDURE Radical Prostatectomy
- PROCEDURE Precision Prostatectomy
Study Locations (1)
Michigan
- Henry Ford Health - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-01-12 |
| Est. Completion | 2028-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07348367
The ClinicalTrials.gov registry entry for NCT07348367 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 91-participant average among 4 other Prostatectomy trials with a reported enrollment target (76% higher). The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatectomy appearing as the primary indexed condition, and to 2 interventions - of which Radical Prostatectomy is the first listed.
NCT07348367 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT07348367 about?
NCT07348367 is a clinical study titled "A Comparison of Radical Prostatectomy and Precision Prostatectomy in Low- and Intermediate-risk Prostate Cancers.". Prostate cancer (PCa) management for low- and intermediate-risk patients often involves radical prostatectomy (RP), which achieves oncologic control but is associated with significant functional impairments, such as erectile dysfunction (50-70%) and urinary incontinence (5-20%). To address these iss...
What is the current status of trial NCT07348367?
This trial is currently recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2026-01-12. Estimated completion is 2028-12.
What conditions does trial NCT07348367 study?
This clinical trial studies the following conditions: Prostatectomy.
What interventions are being tested in trial NCT07348367?
The interventions under investigation include: Radical Prostatectomy (PROCEDURE), Precision Prostatectomy (PROCEDURE).
Who is sponsoring clinical trial NCT07348367?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07348367 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatectomy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
RECRUITING · NA
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Magnesium Sulfate as an Adjunctive Analgesic in Prostate Surgery
ACTIVE NOT RECRUITING · Phase 4
-
TAP-patients With Robotic Assisted Lap Prostatectomy
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.